Supreeth, Medical Oncologist at Sri Shankara Cancer Hospital, shared on X:
“Dyslipidemia is a common adverse effect of Lorlatinib. In today’s Clinical pearls in oncology let’s understand a few basics of its incidence, grading, testing and management based on this case, before referring to an Endocrinologist or an internist for management!”
More in the gallery.
You might be interested in:
Lung Cancer in Nonsmoking Individuals: A Distinct Clinical Profile
